董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Bisaro | -- | Chairman of the Board | -- | 未披露 | 未持股 | 2023-02-02 |
| Daniel Celentano | -- | Director | -- | 未披露 | 未持股 | 2023-02-02 |
| Riad El Dada | -- | Director | -- | 未披露 | 未持股 | 2023-02-02 |
| Neal Goldman | -- | Director | -- | 未披露 | 未持股 | 2023-02-02 |
| Karen Ling | -- | Director | -- | 未披露 | 未持股 | 2023-02-02 |
| Woodrow Myers | -- | Director | -- | 未披露 | 未持股 | 2023-02-02 |
| Susan Silbermann | -- | -- | -- | 未披露 | 未持股 | 2023-02-02 |
| James Sulat | -- | Director | -- | 未披露 | 未持股 | 2023-02-02 |
| Sigurdur O. Olafsson | 男 | President, Chief Executive Officer and Director | 54 | 未披露 | 未持股 | 2023-02-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bryan Reasons | 男 | Executive Vice President and Chief Financial Officer | 55 | 未披露 | 未持股 | 2023-02-02 |
| Peter Richardson | 男 | Executive Vice President and Chief Scientific Officer | 63 | 未披露 | 未持股 | 2023-02-02 |
| Stephen Welch | 男 | Executive Vice President and Head of Specialty Generics | 45 | 未披露 | 未持股 | 2023-02-02 |
| Mark Tyndall | 男 | Executive Vice President and Chief Legal Officer and Company Secretary | 47 | 未披露 | 未持股 | 2023-02-02 |
| Kassie Harrold | 女 | Executive Vice President and Chief Compliance Officer | 43 | 未披露 | 未持股 | 2023-02-02 |
| Lisa French | 女 | Executive Vice President and Chief Commercial Officer | 54 | 未披露 | 未持股 | 2023-02-02 |
| Henriette Nielsen | 女 | Executive Vice President and Chief Transformation Officer | 57 | 未披露 | 未持股 | 2023-02-02 |
| Jason Goodson | 男 | Executive Vice President and Head of Corporate Development | 42 | 未披露 | 未持股 | 2023-02-02 |
| Sigurdur O. Olafsson | 男 | President, Chief Executive Officer and Director | 54 | 未披露 | 未持股 | 2023-02-02 |
董事简历
中英对照 | 中文 | 英文- Paul Bisaro
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Daniel Celentano
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Riad El Dada
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Neal Goldman
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Karen Ling
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Woodrow Myers
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Susan Silbermann
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- James Sulat
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sigurdur O. Olafsson
-
Sigurdur O. Olafsson，现为Actavis Pharma的总裁；于2010年9月加入Actavis，担任全球仿制药物执行副总裁；2012年4月，被任命为全球仿制药业务总裁；2013年10月起，担任本公司董事。加入Actavis之前，2008-2010，他担任Actavis Group的首席执行官，负责全球40多个国家药品业务的监督。2006-2008，他担任Actavis Group的副首席执行官；2003-2006，担任美国地区首席执行官、企业发展首席官，领导销售和营销工作。加入Actavis Group之前，1998-2003，他在Pfizer的美国和英国全球研发团队担任了愈益重要的多个职务，还在爱尔兰担任了4年的Omega Farma药物开发总监。他在University of Iceland获得药剂与药物硕士学位。
Sigurdur O. Olafsson is the President, Actavis Pharma and joined Actavis as Executive Vice President, Global Generics in September 2010 and was appointed President of the Global Generics business in April 2012. Mr. Olafsson was also appointed as a member of Mallinckrodt Plc Board of Directors since October 2013. Prior to joining Actavis, Mr. Olafsson served as Chief Executive Officer of the Actavis Group from 2008 to 2010 where he was responsible for overseeing its global pharmaceuticals business with operations in more than 40 countries. From 2006 until 2008 Mr. Olafsson served as Deputy CEO of the Actavis Group and was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development from 2003 to 2006 where he led Actavis' sales and marketing organization. Prior to joining the Actavis Group, he held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and the U.K. from 1998 to 2003 and served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy Cand Pharm from the University of Iceland. - Sigurdur O. Olafsson，现为Actavis Pharma的总裁；于2010年9月加入Actavis，担任全球仿制药物执行副总裁；2012年4月，被任命为全球仿制药业务总裁；2013年10月起，担任本公司董事。加入Actavis之前，2008-2010，他担任Actavis Group的首席执行官，负责全球40多个国家药品业务的监督。2006-2008，他担任Actavis Group的副首席执行官；2003-2006，担任美国地区首席执行官、企业发展首席官，领导销售和营销工作。加入Actavis Group之前，1998-2003，他在Pfizer的美国和英国全球研发团队担任了愈益重要的多个职务，还在爱尔兰担任了4年的Omega Farma药物开发总监。他在University of Iceland获得药剂与药物硕士学位。
- Sigurdur O. Olafsson is the President, Actavis Pharma and joined Actavis as Executive Vice President, Global Generics in September 2010 and was appointed President of the Global Generics business in April 2012. Mr. Olafsson was also appointed as a member of Mallinckrodt Plc Board of Directors since October 2013. Prior to joining Actavis, Mr. Olafsson served as Chief Executive Officer of the Actavis Group from 2008 to 2010 where he was responsible for overseeing its global pharmaceuticals business with operations in more than 40 countries. From 2006 until 2008 Mr. Olafsson served as Deputy CEO of the Actavis Group and was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development from 2003 to 2006 where he led Actavis' sales and marketing organization. Prior to joining the Actavis Group, he held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and the U.K. from 1998 to 2003 and served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy Cand Pharm from the University of Iceland.
高管简历
中英对照 | 中文 | 英文- Bryan Reasons
Bryan Reasons是我们的执行Vice President和首席财务官。他对全球金融功能负有执行责任。在2019年3月加入Mallinckrodt之前，Reasons先生于2018年5月至2019年1月担任AmnealPharmaceuticals，Inc.Amneal的高级副总裁兼首席财务官，并担任Impax Laboratories的高级副总裁，财务和首席财务官，Inc.从2012年12月起“Impax”，直到Amneal Pharmaceuticals LLC和Impax于2018年5月完成业务合并成立Amneal。Reasons先生此前曾于2012年6月至2012年12月担任Impax的代理首席财务官，并于2012年1月至2012年6月担任Impax的财务Vice President。在2012年1月加入Impax之前，他曾于2005年至2012年在Cephalon，Inc.和2003年至2005年在E.I.Du Pont De Nemours And Company担任多个财务管理职位，并于1993年至2003年在普华永道会计师事务所担任高级经理。Reasons先生还担任AclarisTherapeutics，Inc.和RecroPharma，Inc.的独立董事和审计委员会主席。
Bryan Reasons,is Mallinckrodt Plc Executive Vice President ("EVP") and Chief Financial Officer ("CFO"). He has executive responsibility for the global finance function. Prior to joining Mallinckrodt in March 2019, Mr. Reasons served as Senior Vice President ("SVP") and CFO of Amneal Pharmaceuticals, Inc. from May 2018 until January 2019 and as SVP, Finance and CFO of Impax Laboratories, Inc. from December 2012 until Amneal and Impax completed their business combination to form Amneal in May 2018. Mr. Reasons previously served as Impax's Acting CFO from June 2012 to December 2012 and as Impax's Vice President ("VP"), Finance from January 2012 to June 2012. Prior to joining Impax in January 2012, he held various finance management positions at Cephalon, Inc. from 2005 to 2012 and at E. I. Du Pont De Nemours and Company from 2003 to 2005 and was at PricewaterhouseCoopers LLP ("PwC") from 1993 to 2003, last serving as senior manager. Mr. Reasons also serves as an independent board director and audit committee chair for both Aclaris Therapeutics, Inc. and Recro Pharma, Inc.- Bryan Reasons是我们的执行Vice President和首席财务官。他对全球金融功能负有执行责任。在2019年3月加入Mallinckrodt之前，Reasons先生于2018年5月至2019年1月担任AmnealPharmaceuticals，Inc.Amneal的高级副总裁兼首席财务官，并担任Impax Laboratories的高级副总裁，财务和首席财务官，Inc.从2012年12月起“Impax”，直到Amneal Pharmaceuticals LLC和Impax于2018年5月完成业务合并成立Amneal。Reasons先生此前曾于2012年6月至2012年12月担任Impax的代理首席财务官，并于2012年1月至2012年6月担任Impax的财务Vice President。在2012年1月加入Impax之前，他曾于2005年至2012年在Cephalon，Inc.和2003年至2005年在E.I.Du Pont De Nemours And Company担任多个财务管理职位，并于1993年至2003年在普华永道会计师事务所担任高级经理。Reasons先生还担任AclarisTherapeutics，Inc.和RecroPharma，Inc.的独立董事和审计委员会主席。
- Bryan Reasons,is Mallinckrodt Plc Executive Vice President ("EVP") and Chief Financial Officer ("CFO"). He has executive responsibility for the global finance function. Prior to joining Mallinckrodt in March 2019, Mr. Reasons served as Senior Vice President ("SVP") and CFO of Amneal Pharmaceuticals, Inc. from May 2018 until January 2019 and as SVP, Finance and CFO of Impax Laboratories, Inc. from December 2012 until Amneal and Impax completed their business combination to form Amneal in May 2018. Mr. Reasons previously served as Impax's Acting CFO from June 2012 to December 2012 and as Impax's Vice President ("VP"), Finance from January 2012 to June 2012. Prior to joining Impax in January 2012, he held various finance management positions at Cephalon, Inc. from 2005 to 2012 and at E. I. Du Pont De Nemours and Company from 2003 to 2005 and was at PricewaterhouseCoopers LLP ("PwC") from 1993 to 2003, last serving as senior manager. Mr. Reasons also serves as an independent board director and audit committee chair for both Aclaris Therapeutics, Inc. and Recro Pharma, Inc.
- Peter Richardson
彼得理查森，MRCP，现任Mallinckrodt Plc执行副总裁兼首席科学官，于2023年1月上任。他负责Mallinckrodt的品牌研发、医疗事务、安全、投资组合和项目管理以及监管事务职能。Richardson博士是一名制药高管，在研发领导方面拥有30多年的经验，包括建立和支持产品开发管道和临床项目管理。在加入公司之前，Richardson博士曾担任Antares Pharmaceuticals，Inc.的执行副总裁兼首席医疗官，领导该组织的研发活动。在加入Antares Pharmaceuticals，Inc.之前，他曾在多家制药公司担任研发高级领导职务，包括诺华、MannKind Corporation和Adare Pharmaceuticals。Richardson博士在诺丁汉大学获得医学学士学位，在诺丁汉大学医学院获得医学学士学位和外科学士学位。他完成了斯坦福大学商学院的高管课程，并且是英国皇家内科医学院的成员。
Peter Richardson,MRCP, is Mallinckrodt Plc EVP and Chief Scientific Officer, a role he assumed in January 2023. He has executive responsibility for Mallinckrodt's branded research and development, medical affairs, safety, portfolio and project management, and regulatory affairs functions. Dr. Richardson is a pharmaceutical executive with more than 30 years of experience in research and development leadership, including building and supporting product development pipelines and clinical program management. Prior to joining the Company, Dr. Richardson served as EVP and Chief Medical Officer at Antares Pharmaceuticals, Inc . leading the organization's research and development activities. Prior to Antares Pharmaceuticals, Inc. he held senior leadership positions in research and development at several pharmaceutical companies, including Novartis, MannKind Corporation and Adare Pharmaceuticals. Dr. Richardson earned his Bachelor of Medical Sciences from the University of Nottingham and his Bachelor of Medicine and Bachelor of Surgery from the University of Nottingham Medical School. He completed Stanford University Graduate School of Business' executive program and is a member of the Royal College of Physicians in the United Kingdom.- 彼得理查森，MRCP，现任Mallinckrodt Plc执行副总裁兼首席科学官，于2023年1月上任。他负责Mallinckrodt的品牌研发、医疗事务、安全、投资组合和项目管理以及监管事务职能。Richardson博士是一名制药高管，在研发领导方面拥有30多年的经验，包括建立和支持产品开发管道和临床项目管理。在加入公司之前，Richardson博士曾担任Antares Pharmaceuticals，Inc.的执行副总裁兼首席医疗官，领导该组织的研发活动。在加入Antares Pharmaceuticals，Inc.之前，他曾在多家制药公司担任研发高级领导职务，包括诺华、MannKind Corporation和Adare Pharmaceuticals。Richardson博士在诺丁汉大学获得医学学士学位，在诺丁汉大学医学院获得医学学士学位和外科学士学位。他完成了斯坦福大学商学院的高管课程，并且是英国皇家内科医学院的成员。
- Peter Richardson,MRCP, is Mallinckrodt Plc EVP and Chief Scientific Officer, a role he assumed in January 2023. He has executive responsibility for Mallinckrodt's branded research and development, medical affairs, safety, portfolio and project management, and regulatory affairs functions. Dr. Richardson is a pharmaceutical executive with more than 30 years of experience in research and development leadership, including building and supporting product development pipelines and clinical program management. Prior to joining the Company, Dr. Richardson served as EVP and Chief Medical Officer at Antares Pharmaceuticals, Inc . leading the organization's research and development activities. Prior to Antares Pharmaceuticals, Inc. he held senior leadership positions in research and development at several pharmaceutical companies, including Novartis, MannKind Corporation and Adare Pharmaceuticals. Dr. Richardson earned his Bachelor of Medical Sciences from the University of Nottingham and his Bachelor of Medicine and Bachelor of Surgery from the University of Nottingham Medical School. He completed Stanford University Graduate School of Business' executive program and is a member of the Royal College of Physicians in the United Kingdom.
- Stephen Welch
斯蒂芬韦尔奇是Mallinckrodt Plc执行副总裁兼特种仿制药主管，于2022年8月上任。他对公司的特种仿制药部门负有执行责任，直接管理该部门业务的各个方面。在此之前的2022年1月至2022年8月，韦尔奇曾担任Mallinckrodt Plc高级副总裁兼特种仿制药总经理。他曾于2020年12月至2022年1月担任该部门的CFO，并于2019年8月至2022年6月担任Mallinckrodt的CTO，包括在公司的第11章程序期间，并定期代表公司参与这些程序。他于2012年加入Mallinckrodt，在公司任职期间，他担任过许多越来越具有战略性的职务，包括总裁兼首席执行官的办公室主任和公司战略副总裁。他开始在Mallinckrodt的税务部门工作，主要关注并购交易和业务整合。在加入Mallinckrodt之前，韦尔奇曾在Human Genome Sciences和PharMerica负责税务工作。他的职业生涯始于普华永道。韦尔奇拥有乔治城大学法律中心法学博士学位和加州州立大学贝克斯菲尔德分校政治学学士学位。
Stephen Welch,is Mallinckrodt Plc EVP and Head of Specialty Generics, a role he assumed in August 2022. He has executive responsibility for the Company's Specialty Generics segment, directly managing all aspects of the segment's business. Before that, from January 2022 to August 2022, Mr. Welch served as Mallinckrodt Plc SVP and General Manager, Specialty Generics. He previously served as the segment's CFO from December 2020 to January 2022 and CTO for Mallinckrodt from August 2019 to June 2022, including during the Company's Chapter 11 process, and regularly represented the Company in those proceedings. He joined Mallinckrodt in 2012 and during his time with the Company has held a number of increasingly strategic roles, including Chief of Staff to the President and CEO and Vice President of Corporate Strategy. He began his time at Mallinckrodt in the tax department, focused primarily on mergers and acquisitions transactions and business integrations. Prior to joining Mallinckrodt, Mr. Welch led the tax function at Human Genome Sciences and PharMerica. He began his career at PwC. Mr. Welch holds a J.D. from the Georgetown University Law Center and a Bachelor's degree in Political Science from California State University, Bakersfield.- 斯蒂芬韦尔奇是Mallinckrodt Plc执行副总裁兼特种仿制药主管，于2022年8月上任。他对公司的特种仿制药部门负有执行责任，直接管理该部门业务的各个方面。在此之前的2022年1月至2022年8月，韦尔奇曾担任Mallinckrodt Plc高级副总裁兼特种仿制药总经理。他曾于2020年12月至2022年1月担任该部门的CFO，并于2019年8月至2022年6月担任Mallinckrodt的CTO，包括在公司的第11章程序期间，并定期代表公司参与这些程序。他于2012年加入Mallinckrodt，在公司任职期间，他担任过许多越来越具有战略性的职务，包括总裁兼首席执行官的办公室主任和公司战略副总裁。他开始在Mallinckrodt的税务部门工作，主要关注并购交易和业务整合。在加入Mallinckrodt之前，韦尔奇曾在Human Genome Sciences和PharMerica负责税务工作。他的职业生涯始于普华永道。韦尔奇拥有乔治城大学法律中心法学博士学位和加州州立大学贝克斯菲尔德分校政治学学士学位。
- Stephen Welch,is Mallinckrodt Plc EVP and Head of Specialty Generics, a role he assumed in August 2022. He has executive responsibility for the Company's Specialty Generics segment, directly managing all aspects of the segment's business. Before that, from January 2022 to August 2022, Mr. Welch served as Mallinckrodt Plc SVP and General Manager, Specialty Generics. He previously served as the segment's CFO from December 2020 to January 2022 and CTO for Mallinckrodt from August 2019 to June 2022, including during the Company's Chapter 11 process, and regularly represented the Company in those proceedings. He joined Mallinckrodt in 2012 and during his time with the Company has held a number of increasingly strategic roles, including Chief of Staff to the President and CEO and Vice President of Corporate Strategy. He began his time at Mallinckrodt in the tax department, focused primarily on mergers and acquisitions transactions and business integrations. Prior to joining Mallinckrodt, Mr. Welch led the tax function at Human Genome Sciences and PharMerica. He began his career at PwC. Mr. Welch holds a J.D. from the Georgetown University Law Center and a Bachelor's degree in Political Science from California State University, Bakersfield.
- Mark Tyndall
Mark Tyndall是Mallinckrodt Plc执行副总裁、首席法务官和公司秘书，于2022年8月上任。Tyndall先生对所有法律职能负有执行责任，并担任董事会的主要联络人。他还负责Mallinckrodt的政府事务和患者权益倡导职能。此前，从2021年2月到2022年8月，廷德尔曾担任Mallinckrodt的高级副总裁和美国总法律顾问，负责美国和国际商业法律团队、公司诉讼和调查、法律运作以及公司隐私职能，并监督政府事务团队。在此之前，廷德尔于2019年2月至2021年2月担任政府事务高级副总裁兼首席诉讼顾问，并于2014年6月至2019年2月担任政府事务、政策和患者权益倡导副总裁。在加入Mallinckrodt之前，廷德尔曾在拜耳医疗保健的消费者健康部门担任全球政策和公共事务主管，2013年1月至2014年6月担任这一职务。在加入拜耳之前，Tyndall先生在Sidley Austin LLP的华盛顿特区办公室从事医疗保健和政治法工作，专注于医疗保健监管问题、欺诈和滥用问题以及立法和政策问题。他还是美国参议院农业、营养和林业委员会的前专业工作人员。Tyndall先生拥有乔治华盛顿大学法学院法学博士学位（“J.D.”）、威廉和玛丽学院公共政策硕士学位以及克里斯托弗纽波特大学经济学文学士学位（“B.A.”）。他还在牛津大学新学院完成了国际人权法暑期课程。
Mark Tyndall,is Mallinckrodt Plc EVP, Chief Legal Officer, and Corporate Secretary, roles he assumed in August 2022. Mr. Tyndall has executive responsibility for all legal functions and serves as the primary liaison to the Board of Directors. He also has responsibility for Mallinckrodt's Government Affairs and Patient Advocacy functions. Previously, from February 2021 to August 2022, Mr. Tyndall served as Mallinckrodt's SVP and U.S. General Counsel, where he had responsibility for the U.S. and international commercial legal teams, corporate litigation and investigations, legal operations, and the corporate privacy function, and oversaw the Government Affairs team. Before that, Mr. Tyndall held the roles of SVP of Government Affairs and Chief Counsel of Litigation from February 2019 to February 2021, and VP of Government Affairs, Policy and Patient Advocacy from June 2014 to February 2019. Prior to Mallinckrodt, Mr. Tyndall served as Head of Global Policy and Public Affairs at Bayer Healthcare's consumer health division, a role he served in from January 2013 to June 2014. Prior to joining Bayer, Mr. Tyndall practiced healthcare and political law in the Washington, D.C. office of Sidley Austin LLP, where he focused on healthcare regulatory issues, fraud and abuse matters and legislative and policy issues. He is also a former professional staff member of the U.S. Senate Committee on Agriculture, Nutrition and Forestry. Mr. Tyndall holds a Juris Doctor ("J.D.") from George Washington University Law School, a Master of Public Policy from the College of William and Mary, and a Bachelor of Arts ("B.A.") degree in Economics from Christopher Newport University. He also completed the International Human Rights Law Summer Program at the University of Oxford, New College.- Mark Tyndall是Mallinckrodt Plc执行副总裁、首席法务官和公司秘书，于2022年8月上任。Tyndall先生对所有法律职能负有执行责任，并担任董事会的主要联络人。他还负责Mallinckrodt的政府事务和患者权益倡导职能。此前，从2021年2月到2022年8月，廷德尔曾担任Mallinckrodt的高级副总裁和美国总法律顾问，负责美国和国际商业法律团队、公司诉讼和调查、法律运作以及公司隐私职能，并监督政府事务团队。在此之前，廷德尔于2019年2月至2021年2月担任政府事务高级副总裁兼首席诉讼顾问，并于2014年6月至2019年2月担任政府事务、政策和患者权益倡导副总裁。在加入Mallinckrodt之前，廷德尔曾在拜耳医疗保健的消费者健康部门担任全球政策和公共事务主管，2013年1月至2014年6月担任这一职务。在加入拜耳之前，Tyndall先生在Sidley Austin LLP的华盛顿特区办公室从事医疗保健和政治法工作，专注于医疗保健监管问题、欺诈和滥用问题以及立法和政策问题。他还是美国参议院农业、营养和林业委员会的前专业工作人员。Tyndall先生拥有乔治华盛顿大学法学院法学博士学位（“J.D.”）、威廉和玛丽学院公共政策硕士学位以及克里斯托弗纽波特大学经济学文学士学位（“B.A.”）。他还在牛津大学新学院完成了国际人权法暑期课程。
- Mark Tyndall,is Mallinckrodt Plc EVP, Chief Legal Officer, and Corporate Secretary, roles he assumed in August 2022. Mr. Tyndall has executive responsibility for all legal functions and serves as the primary liaison to the Board of Directors. He also has responsibility for Mallinckrodt's Government Affairs and Patient Advocacy functions. Previously, from February 2021 to August 2022, Mr. Tyndall served as Mallinckrodt's SVP and U.S. General Counsel, where he had responsibility for the U.S. and international commercial legal teams, corporate litigation and investigations, legal operations, and the corporate privacy function, and oversaw the Government Affairs team. Before that, Mr. Tyndall held the roles of SVP of Government Affairs and Chief Counsel of Litigation from February 2019 to February 2021, and VP of Government Affairs, Policy and Patient Advocacy from June 2014 to February 2019. Prior to Mallinckrodt, Mr. Tyndall served as Head of Global Policy and Public Affairs at Bayer Healthcare's consumer health division, a role he served in from January 2013 to June 2014. Prior to joining Bayer, Mr. Tyndall practiced healthcare and political law in the Washington, D.C. office of Sidley Austin LLP, where he focused on healthcare regulatory issues, fraud and abuse matters and legislative and policy issues. He is also a former professional staff member of the U.S. Senate Committee on Agriculture, Nutrition and Forestry. Mr. Tyndall holds a Juris Doctor ("J.D.") from George Washington University Law School, a Master of Public Policy from the College of William and Mary, and a Bachelor of Arts ("B.A.") degree in Economics from Christopher Newport University. He also completed the International Human Rights Law Summer Program at the University of Oxford, New College.
- Kassie Harrold
Kassie Harrold是Mallinckrodt Plc执行副总裁兼CCO，于2022年8月上任。哈罗德负责监督Mallinckrodt的全球诚信和合规项目。在此之前，Harrold女士曾担任Mallinckrodt Plc高级副总裁和CCO，负责全球道德和合规项目，包括风险评估和缓解、热线报告和调查、项目监测和治理。Harrold女士在制药和特种化学品行业拥有超过15年的合规经验，在广泛的主题领域评估、实施和管理合规项目。自2013年加入Mallinckrodt以来，Harrold女士承担了越来越多的职责，包括领导贸易合规和业务支持职能，并作为总裁和首席执行官的高级员工联络员就广泛的业务事项向高级管理层提供咨询。此前，哈罗德女士曾在孟山都旗下的特种化学品公司Solutia Inc.担任多个职位，包括全球合规、诉讼和就业顾问以及政府事务。Harrold女士是保健女企业家协会（“HBA”）的成员，曾在圣路易斯分会董事会任职。她还作为CCO圆桌会议成员参加了药品合规论坛。她在宾夕法尼亚州匹兹堡的杜肯大学获得了理学学士（“B.S.”）和法学博士学位。
Kassie Harrold,is Mallinckrodt Plc EVP and CCO, a role she assumed in August 2022. Ms. Harrold has executive responsibility for overseeing Mallinckrodt's global integrity and compliance program. Previously, Ms. Harrold served as Mallinckrodt Plc SVP and CCO, with responsibility for global ethics and the compliance program, including risk assessment and mitigation, hotline reporting and investigations, program monitoring and governance. Ms. Harrold has more than 15 years of compliance experience in the pharmaceutical and specialty chemical industries, and has assessed, implemented and managed compliance programs in a broad range of subject matter areas. Ms. Harrold has held roles of increasing responsibility since joining Mallinckrodt in 2013, including leading the trade compliance and business support functions and advising senior management on a broad range of business matters as the Senior Staff Liaison to the President and CEO. Previously, Ms. Harrold held several positions, including global compliance, litigation and employment counsel and government affairs, with Solutia Inc., the specialty chemicals spin-off of Monsanto. Ms. Harrold is a member of the Healthcare Businesswomen's Association ("HBA"), previously serving on the St. Louis chapter board. She also participates in the Pharmaceutical Compliance Forum as a member of the CCO Roundtable. She earned her Bachelor of Science ("B.S.") and J.D. degrees from Duquesne University in Pittsburgh, Pennsylvania.- Kassie Harrold是Mallinckrodt Plc执行副总裁兼CCO，于2022年8月上任。哈罗德负责监督Mallinckrodt的全球诚信和合规项目。在此之前，Harrold女士曾担任Mallinckrodt Plc高级副总裁和CCO，负责全球道德和合规项目，包括风险评估和缓解、热线报告和调查、项目监测和治理。Harrold女士在制药和特种化学品行业拥有超过15年的合规经验，在广泛的主题领域评估、实施和管理合规项目。自2013年加入Mallinckrodt以来，Harrold女士承担了越来越多的职责，包括领导贸易合规和业务支持职能，并作为总裁和首席执行官的高级员工联络员就广泛的业务事项向高级管理层提供咨询。此前，哈罗德女士曾在孟山都旗下的特种化学品公司Solutia Inc.担任多个职位，包括全球合规、诉讼和就业顾问以及政府事务。Harrold女士是保健女企业家协会（“HBA”）的成员，曾在圣路易斯分会董事会任职。她还作为CCO圆桌会议成员参加了药品合规论坛。她在宾夕法尼亚州匹兹堡的杜肯大学获得了理学学士（“B.S.”）和法学博士学位。
- Kassie Harrold,is Mallinckrodt Plc EVP and CCO, a role she assumed in August 2022. Ms. Harrold has executive responsibility for overseeing Mallinckrodt's global integrity and compliance program. Previously, Ms. Harrold served as Mallinckrodt Plc SVP and CCO, with responsibility for global ethics and the compliance program, including risk assessment and mitigation, hotline reporting and investigations, program monitoring and governance. Ms. Harrold has more than 15 years of compliance experience in the pharmaceutical and specialty chemical industries, and has assessed, implemented and managed compliance programs in a broad range of subject matter areas. Ms. Harrold has held roles of increasing responsibility since joining Mallinckrodt in 2013, including leading the trade compliance and business support functions and advising senior management on a broad range of business matters as the Senior Staff Liaison to the President and CEO. Previously, Ms. Harrold held several positions, including global compliance, litigation and employment counsel and government affairs, with Solutia Inc., the specialty chemicals spin-off of Monsanto. Ms. Harrold is a member of the Healthcare Businesswomen's Association ("HBA"), previously serving on the St. Louis chapter board. She also participates in the Pharmaceutical Compliance Forum as a member of the CCO Roundtable. She earned her Bachelor of Science ("B.S.") and J.D. degrees from Duquesne University in Pittsburgh, Pennsylvania.
- Lisa French
Lisa French是Mallinckrodt Plc执行副总裁兼首席商务官，于2022年10月上任。她负责公司专业品牌产品的所有商业和市场准入活动，以及Mallinckrodt近期开发组合中资产的新产品发布执行。French女士在美国市场商业化战略制定和整个治疗生命周期的运营经验方面拥有30多年的经验。在加入公司之前，她曾担任全球医疗保健公司Organon & Co.的美国业务部门主管，并在那里领导商业团队。在此之前，她在默克担任过多个职位，职责越来越重，在那里，她最终领导了一个价值数十亿美元的品牌的各个方面，执行商业创新计划，并监督多个销售团队。她担任的职务包括：副总裁，HPV特许经营美国市场主管；美国战略和商业模式创新副总裁；美国联邦政策执行董事；全国商业运营（女性健康）执行董事；全国30级商业运营（HIV）总监；商业运营（慢性护理）区域总监；商业运营（心血管护理）区域总监等职务。弗伦奇在西切斯特大学获得了生物学学士学位，并完成了哈佛商学院的“新锐领袖”和“领导力与战略”高管课程。
Lisa French,is Mallinckrodt Plc EVP and Chief Commercial Officer, a role she assumed in October 2022. She has executive responsibility for all commercial and market-access activities for the Company's Specialty Brands products, as well as new product launch execution for assets in Mallinckrodt's near-term development portfolio. Ms. French has more than 30 years of experience in U.S. go-to-market commercialization strategy development and operating experience across the therapeutics lifecycle. Prior to joining the Company, she served as U.S. Business Unit Lead of Organon & Co.'s, a global healthcare company, Women's Health Franchise, where she led the commercial team. Prior to that, she held various positions of increasing responsibility at Merck, where she ultimately led all aspects of a multi-billion dollar brand, executed commercial innovation initiatives and oversaw multiple sales teams. Her roles included: Associate Vice President, U.S. Marketing Lead – HPV Franchise; Vice President of U.S. Strategy and Commercial Model Innovation; Executive Director of U.S. Federal Policy; National Executive Director of Commercial Operations – Women's Health; National 30 Director of Commercial Operations – HIV; Regional Director of Commercial Operations – Chronic Care; and Regional Director of Commercial Operations – Cardiovascular Care, among other roles. Ms. French earned her B.S. in Biology from West Chester University and completed Harvard Business School's Emerging Leaders and Leadership & Strategy executive programs.- Lisa French是Mallinckrodt Plc执行副总裁兼首席商务官，于2022年10月上任。她负责公司专业品牌产品的所有商业和市场准入活动，以及Mallinckrodt近期开发组合中资产的新产品发布执行。French女士在美国市场商业化战略制定和整个治疗生命周期的运营经验方面拥有30多年的经验。在加入公司之前，她曾担任全球医疗保健公司Organon & Co.的美国业务部门主管，并在那里领导商业团队。在此之前，她在默克担任过多个职位，职责越来越重，在那里，她最终领导了一个价值数十亿美元的品牌的各个方面，执行商业创新计划，并监督多个销售团队。她担任的职务包括：副总裁，HPV特许经营美国市场主管；美国战略和商业模式创新副总裁；美国联邦政策执行董事；全国商业运营（女性健康）执行董事；全国30级商业运营（HIV）总监；商业运营（慢性护理）区域总监；商业运营（心血管护理）区域总监等职务。弗伦奇在西切斯特大学获得了生物学学士学位，并完成了哈佛商学院的“新锐领袖”和“领导力与战略”高管课程。
- Lisa French,is Mallinckrodt Plc EVP and Chief Commercial Officer, a role she assumed in October 2022. She has executive responsibility for all commercial and market-access activities for the Company's Specialty Brands products, as well as new product launch execution for assets in Mallinckrodt's near-term development portfolio. Ms. French has more than 30 years of experience in U.S. go-to-market commercialization strategy development and operating experience across the therapeutics lifecycle. Prior to joining the Company, she served as U.S. Business Unit Lead of Organon & Co.'s, a global healthcare company, Women's Health Franchise, where she led the commercial team. Prior to that, she held various positions of increasing responsibility at Merck, where she ultimately led all aspects of a multi-billion dollar brand, executed commercial innovation initiatives and oversaw multiple sales teams. Her roles included: Associate Vice President, U.S. Marketing Lead – HPV Franchise; Vice President of U.S. Strategy and Commercial Model Innovation; Executive Director of U.S. Federal Policy; National Executive Director of Commercial Operations – Women's Health; National 30 Director of Commercial Operations – HIV; Regional Director of Commercial Operations – Chronic Care; and Regional Director of Commercial Operations – Cardiovascular Care, among other roles. Ms. French earned her B.S. in Biology from West Chester University and completed Harvard Business School's Emerging Leaders and Leadership & Strategy executive programs.
- Henriette Nielsen
Henriette Nielsen是Mallinckrodt Plc执行副总裁兼首席转型官（CTO），于2022年8月上任。尼尔森女士负责所有人力资源、沟通和与人有关的事务，并专注于进一步建设Mallinckrodt Plc环境、社会和治理项目。尼尔森女士从一系列公司职能中获得了丰富的经验，并在加强制药公司的业务方面取得了令人印象深刻的记录。此前，尼尔森曾在Hikma担任业务运营执行副总裁，2018年至2022年担任该职位。在此之前，尼尔森于2015年至2018年在梯瓦担任全球营销和产品组合高级副总裁、CTO，并于2014年至2015年担任全球仿制药高级副总裁、CTO。在此之前，她于2011年至2014年担任医疗保健和影响力投资咨询公司System Matters APS的创始人，并于2006年至2011年担任阿特维斯集团的总法律顾问和执行副总裁。尼尔森的职业生涯始于丹麦Kromann Reumert的一名商业律师。她目前担任Think Equal USA的副主席，这是一家提供和倡导早期社会情感学习的非盈利机构，也是EIR的顾问，该机构在丹麦推广女子运动。从2017年到2018年，她担任PGT Healthcare的董事会成员和观察员，该公司是梯瓦和宝洁公司的合资企业。尼尔森女士是哥本哈根大学法律专业的候选人，在爱丁堡大学获得法学硕士学位，并在牛津大学完成了领先可持续公司项目。
Henriette Nielsen,is Mallinckrodt Plc EVP and Chief Transformation Officer ("CTO"), a role she assumed in August 2022. Ms. Nielsen has executive responsibility for all human resources, communications and people-related matters, as well as a focus on further building out Mallinckrodt Plc Environment, Social and Governance program. Previously, Ms. Nielsen served at Hikma as EVP, Business Operations, a role she held from 2018 to 2022. Before that, Ms. Nielsen served at Teva as SVP, CTO, Global Marketing and Portfolio from 2015 to 2018, and SVP, CTO, Global Generics Medicine from 2014 to 2015. Before that, she was the founder of System Matters APS, a healthcare and impact investing consultancy from 2011 to 2014 and the general counsel and an executive vice president at Actavis Group from 2006 to 2011. Ms. Nielsen began her career as a commercial lawyer in Denmark at Kromann Reumert. She presently serves as Vice Chair of Think Equal USA, a not-for-profit providing and advocating for early-age social emotional learning, and an advisor to EIR, which promotes women's sports in Denmark. From 2017 to 2018 she served as a board member and observer at PGT Healthcare, a joint venture between Teva and Procter & Gamble Company. Ms. Nielsen was a candidate of law at the University of Copenhagen, received her Master of Laws at the University of Edinburgh, and completed the Leading Sustainable Corporation Program at the University of Oxford.- Henriette Nielsen是Mallinckrodt Plc执行副总裁兼首席转型官（CTO），于2022年8月上任。尼尔森女士负责所有人力资源、沟通和与人有关的事务，并专注于进一步建设Mallinckrodt Plc环境、社会和治理项目。尼尔森女士从一系列公司职能中获得了丰富的经验，并在加强制药公司的业务方面取得了令人印象深刻的记录。此前，尼尔森曾在Hikma担任业务运营执行副总裁，2018年至2022年担任该职位。在此之前，尼尔森于2015年至2018年在梯瓦担任全球营销和产品组合高级副总裁、CTO，并于2014年至2015年担任全球仿制药高级副总裁、CTO。在此之前，她于2011年至2014年担任医疗保健和影响力投资咨询公司System Matters APS的创始人，并于2006年至2011年担任阿特维斯集团的总法律顾问和执行副总裁。尼尔森的职业生涯始于丹麦Kromann Reumert的一名商业律师。她目前担任Think Equal USA的副主席，这是一家提供和倡导早期社会情感学习的非盈利机构，也是EIR的顾问，该机构在丹麦推广女子运动。从2017年到2018年，她担任PGT Healthcare的董事会成员和观察员，该公司是梯瓦和宝洁公司的合资企业。尼尔森女士是哥本哈根大学法律专业的候选人，在爱丁堡大学获得法学硕士学位，并在牛津大学完成了领先可持续公司项目。
- Henriette Nielsen,is Mallinckrodt Plc EVP and Chief Transformation Officer ("CTO"), a role she assumed in August 2022. Ms. Nielsen has executive responsibility for all human resources, communications and people-related matters, as well as a focus on further building out Mallinckrodt Plc Environment, Social and Governance program. Previously, Ms. Nielsen served at Hikma as EVP, Business Operations, a role she held from 2018 to 2022. Before that, Ms. Nielsen served at Teva as SVP, CTO, Global Marketing and Portfolio from 2015 to 2018, and SVP, CTO, Global Generics Medicine from 2014 to 2015. Before that, she was the founder of System Matters APS, a healthcare and impact investing consultancy from 2011 to 2014 and the general counsel and an executive vice president at Actavis Group from 2006 to 2011. Ms. Nielsen began her career as a commercial lawyer in Denmark at Kromann Reumert. She presently serves as Vice Chair of Think Equal USA, a not-for-profit providing and advocating for early-age social emotional learning, and an advisor to EIR, which promotes women's sports in Denmark. From 2017 to 2018 she served as a board member and observer at PGT Healthcare, a joint venture between Teva and Procter & Gamble Company. Ms. Nielsen was a candidate of law at the University of Copenhagen, received her Master of Laws at the University of Edinburgh, and completed the Leading Sustainable Corporation Program at the University of Oxford.
- Jason Goodson
Jason Goodson是Mallinckrodt Plc执行副总裁兼企业发展主管，他于2022年8月上任。古德森先生的行政职责是监督公司战略、业务发展和商业情报。他是一位经验丰富的行政领导，在处理复杂的业务问题和根据公司战略交付成果方面有着良好的记录。Goodson先生曾担任Mallinckrodt Plc业务运营副总裁，负责公司战略、业务发展以及商业情报和分析。Goodson先生还担任总裁兼首席执行官的办公室主任，支持各种战略举措，包括第11章进程中的关键工作流程。古德森先生在各种财务领导、战略和并购交易方面拥有超过18年的经验。他的职业生涯始于Mallinckrodt，担任助理财务总监，在金融机构内专注于并购交易、整合和转型项目。在加入Mallinckrodt之前，Goodson先生曾在SunEdison公司担任各种财务领导职务，包括负责财务转型计划和各种业务发展交易。在加入SunEdison公司之前，他曾在普华永道担任审计业务经理。古德森拥有密苏里大学哥伦比亚分校会计学硕士和学士学位。他是密苏里州的注册会计师。
Jason Goodson,is Mallinckrodt Plc EVP and Head of Corporate Development, a role he assumed in August 2022. Mr. Goodson has executive responsibility for overseeing corporate strategy, business development and business intelligence. He is a seasoned executive leader with a track record of navigating complex business issues and delivering results against corporate strategy. Mr. Goodson previously served as Mallinckrodt Plc VP of Business Operations, where he had responsibility for corporate strategy, business development and business intelligence and analytics. Mr. Goodson has also served as Chief of Staff to the President and CEO supporting various strategic initiatives including key workstreams within the Chapter 11 process. Mr. Goodson has over 18 years of experience in various finance leadership, strategy and mergers and acquisitions transaction focused roles. He began his career at Mallinckrodt as Assistant Controller, within the finance organization focused on mergers and acquisitions transactions, integration and transformation projects. Prior to joining Mallinckrodt, Mr. Goodson was with SunEdison Inc, in various finance leadership roles including responsibility for finance transformation initiatives and various business development transactions. Prior to his time at SunEdison, Inc, he was with PricewaterhouseCoopers as a manager in the audit practice. Mr. Goodson holds Masters and Bachelor's degrees from the University of Missouri–Columbia in Accounting. He is a Certified Public Accountant in the state of Missouri.- Jason Goodson是Mallinckrodt Plc执行副总裁兼企业发展主管，他于2022年8月上任。古德森先生的行政职责是监督公司战略、业务发展和商业情报。他是一位经验丰富的行政领导，在处理复杂的业务问题和根据公司战略交付成果方面有着良好的记录。Goodson先生曾担任Mallinckrodt Plc业务运营副总裁，负责公司战略、业务发展以及商业情报和分析。Goodson先生还担任总裁兼首席执行官的办公室主任，支持各种战略举措，包括第11章进程中的关键工作流程。古德森先生在各种财务领导、战略和并购交易方面拥有超过18年的经验。他的职业生涯始于Mallinckrodt，担任助理财务总监，在金融机构内专注于并购交易、整合和转型项目。在加入Mallinckrodt之前，Goodson先生曾在SunEdison公司担任各种财务领导职务，包括负责财务转型计划和各种业务发展交易。在加入SunEdison公司之前，他曾在普华永道担任审计业务经理。古德森拥有密苏里大学哥伦比亚分校会计学硕士和学士学位。他是密苏里州的注册会计师。
- Jason Goodson,is Mallinckrodt Plc EVP and Head of Corporate Development, a role he assumed in August 2022. Mr. Goodson has executive responsibility for overseeing corporate strategy, business development and business intelligence. He is a seasoned executive leader with a track record of navigating complex business issues and delivering results against corporate strategy. Mr. Goodson previously served as Mallinckrodt Plc VP of Business Operations, where he had responsibility for corporate strategy, business development and business intelligence and analytics. Mr. Goodson has also served as Chief of Staff to the President and CEO supporting various strategic initiatives including key workstreams within the Chapter 11 process. Mr. Goodson has over 18 years of experience in various finance leadership, strategy and mergers and acquisitions transaction focused roles. He began his career at Mallinckrodt as Assistant Controller, within the finance organization focused on mergers and acquisitions transactions, integration and transformation projects. Prior to joining Mallinckrodt, Mr. Goodson was with SunEdison Inc, in various finance leadership roles including responsibility for finance transformation initiatives and various business development transactions. Prior to his time at SunEdison, Inc, he was with PricewaterhouseCoopers as a manager in the audit practice. Mr. Goodson holds Masters and Bachelor's degrees from the University of Missouri–Columbia in Accounting. He is a Certified Public Accountant in the state of Missouri.
- Sigurdur O. Olafsson
Sigurdur O. Olafsson，现为Actavis Pharma的总裁；于2010年9月加入Actavis，担任全球仿制药物执行副总裁；2012年4月，被任命为全球仿制药业务总裁；2013年10月起，担任本公司董事。加入Actavis之前，2008-2010，他担任Actavis Group的首席执行官，负责全球40多个国家药品业务的监督。2006-2008，他担任Actavis Group的副首席执行官；2003-2006，担任美国地区首席执行官、企业发展首席官，领导销售和营销工作。加入Actavis Group之前，1998-2003，他在Pfizer的美国和英国全球研发团队担任了愈益重要的多个职务，还在爱尔兰担任了4年的Omega Farma药物开发总监。他在University of Iceland获得药剂与药物硕士学位。
Sigurdur O. Olafsson is the President, Actavis Pharma and joined Actavis as Executive Vice President, Global Generics in September 2010 and was appointed President of the Global Generics business in April 2012. Mr. Olafsson was also appointed as a member of Mallinckrodt Plc Board of Directors since October 2013. Prior to joining Actavis, Mr. Olafsson served as Chief Executive Officer of the Actavis Group from 2008 to 2010 where he was responsible for overseeing its global pharmaceuticals business with operations in more than 40 countries. From 2006 until 2008 Mr. Olafsson served as Deputy CEO of the Actavis Group and was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development from 2003 to 2006 where he led Actavis' sales and marketing organization. Prior to joining the Actavis Group, he held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and the U.K. from 1998 to 2003 and served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy Cand Pharm from the University of Iceland.- Sigurdur O. Olafsson，现为Actavis Pharma的总裁；于2010年9月加入Actavis，担任全球仿制药物执行副总裁；2012年4月，被任命为全球仿制药业务总裁；2013年10月起，担任本公司董事。加入Actavis之前，2008-2010，他担任Actavis Group的首席执行官，负责全球40多个国家药品业务的监督。2006-2008，他担任Actavis Group的副首席执行官；2003-2006，担任美国地区首席执行官、企业发展首席官，领导销售和营销工作。加入Actavis Group之前，1998-2003，他在Pfizer的美国和英国全球研发团队担任了愈益重要的多个职务，还在爱尔兰担任了4年的Omega Farma药物开发总监。他在University of Iceland获得药剂与药物硕士学位。
- Sigurdur O. Olafsson is the President, Actavis Pharma and joined Actavis as Executive Vice President, Global Generics in September 2010 and was appointed President of the Global Generics business in April 2012. Mr. Olafsson was also appointed as a member of Mallinckrodt Plc Board of Directors since October 2013. Prior to joining Actavis, Mr. Olafsson served as Chief Executive Officer of the Actavis Group from 2008 to 2010 where he was responsible for overseeing its global pharmaceuticals business with operations in more than 40 countries. From 2006 until 2008 Mr. Olafsson served as Deputy CEO of the Actavis Group and was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development from 2003 to 2006 where he led Actavis' sales and marketing organization. Prior to joining the Actavis Group, he held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and the U.K. from 1998 to 2003 and served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy Cand Pharm from the University of Iceland.